



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: July 25, 2008

To: Primary Clinical Research Associates

From: Tracee L. Shevlin
Research Protocol Specialist

Re: N06CA, The Use of Topical Baclofen, Amitriptyline HCl, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study

This study is reopened to patient enrollment at Mayo Clinic Rochester only, per the Status Change Notice dated July 25, 2008.

Please note that NCCTG Addendum 1 has some changes to the protocol and consent forms that only apply to Mayo Clinic Rochester. This addendum may be submitted for expedited review by your IRB, depending on your local IRB policy.

Please feel free to contact with me any questions, at 507-538-6647 or shevlin.tracee@mayo.edu.

Thank you.